Rystiggo is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
MeSH: Myasthenia Gravis
Group: Immunosuppressants;neonatal fragment crystallizable receptor (FcRn) inhibitors